Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation

Journal of Nuclear Medicine

Volumn 47, Issue 2, 2006, Pages 278-286

  Zenz, Thorsten ^a   Schlenk, Richard F ^a   Glatting, Gerhard ^a   Neumaier, Bernd ^a   Blumstein, Norbert ^a   Buchmann, Inga ^a   Von Harsdorf, Stephanie ^a   Ringhoffer, Mark ^a   Wiesneth, Markus ^a   Keller, Frieder ^a   Kotzerke, Jörg ^a   Röttinger, Erwin ^a   Stilgenbauer, Stephan ^a   Döhner, Hartmut ^a   Reske, Sven N ^a   Bunjes, Donald ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

188Re; 90Y; BMT nephropathy; Radioimmunotherapy

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CD66 ANTIBODY RHENIUM 188; CD66 ANTIBODY YTTRIUM 90; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; INDIUM 111; MELPHALAN; RHENIUM 188; THIOTEPA; THYMOCYTE ANTIBODY; TRACER; UNCLASSIFIED DRUG; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DRUG DISTRIBUTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RADIOIMMUNOTHERAPY; ALLOTRANSPLANTATION; BONE MARROW; COHORT ANALYSIS; LEUKEMIA; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; RADIATION EXPOSURE; RADIATION INJURY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE MARROW; BONE MARROW TRANSPLANTATION; COHORT STUDIES; FEMALE; HUMANS; KIDNEY DISEASES; LEUKEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33750385507     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Cohen EP. Renal failure after bone-marrow transplantation. Lancet. 2001;357: 6-7.
2. Parikh CR, McSweeney PA, Korular D, et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int. 2002;62:566-573.
3. Miralbell R, Sancho G, Bieri S, et al. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment. Int J Radiat Oncol Biol Phys. 2004; 58:809-816.
4. Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989;13:210-216.
5. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol. 2003;23: 486-499.
6. Lawton CA, Cohen EP, Barber-Derus SW, et al. Late renal dysfunction in adult survivors of bone marrow transplantation. Cancer. 1991;67:2795-2800.
7. Moulder JE, Fish BL, Abrams RA. Renal toxicity following total-body irradiation and syngeneic bone marrow transplantation. Transplantation. 1987;43: 589-592.
8. Antignac C, Gubler MC, Leverger G, Broyer M, Habib R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int. 1989;35:1336-1344.
9. Iskandar SS, Browning MC, Lorentz WB. Mesangiolytic glomerulopathy in a bone marrow allograft recipient. Hum Pathol. 1989;20:290-292.
10. Juckett M, Perry EH, Daniels BS, Weisdorf DJ. Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1991;7: 405-409.
11. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98: 565-572.
12. Reske SN, Bunjes D, Buchmann I, et al. Targeted bone marrow irradiation in the conditioning of high-risk leukemia prior to stem cell transplantation. Eur J Nucl Med. 2001;28:807-815.
13. Buchmann I, Bunjes D, Kotzerke J, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm. 2002;17:151-163.
14. 90Y-labeled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukemia or myelodysplastic syndrome over the age of 55: results of a phase III study. Br J Haematol 2005;130:604-613.
15. Schubiger P, Hasler P, Novak-Hofer I, Bläuenstein P. Assessment of the binding properties of Granuloszint. Eur J Nucl Med. 1989;15:605-608.
16. Knapp F, Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med. 1994;20:1151-1165.
17. Seitz U, Neumaier B, Glatting G, Kotzerke J, Bunjes D, Reske S. Preparation and evaluation of the rhenium-188-labeled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukemia. Eur J Nucl Med. 1999;26:1265-1273.
18. Kotzerke J, Glatting G, Seitz U, et al. Radioimmunotherapy for the intensification of conditioning prior to stem cell transplantation: differences in dosimetry and biokinetics of Re-188 and Tc-99m-labeled monoclonal anti NCA-95 antibodies. J Nucl Med. 2000;41:531-537.
19. Glatting G, Landmann M, Kull T, et al. Internal radionuclide therapy: the ULMDOS software for treatment planning. Med Phys. 2005;32:2399-2405.
20. Stabin M. MIRDOSE: the personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
21. 131I labeled anti-CD45 antibody combined with cyclophosphamide and total body irradiation. Blood. 1996;85:1122-1131.
22. Matthews D, Appelbaum F, Eary J, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
23. Luxton R, Kunkler P. Radiation nephritis. Acta Radiol Ther Phys Biol. 1964; 2:169-178.
24. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
25. Röttinger EM, Bartkowiak D, Bunjes D, Wennauer R, Dohr D. Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy. Strahlenther Onkol. 2003;179:702-707.
26. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26:69-76.
27. Handgretinger R, Schumm M, Lang P, et al. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci. 1999;872:351-360.
28. Jacobs P, Wood L, Fullard L, Waldmann H, Hale G. T-cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant. 1994;13:763-769.
29. Cohen EP, Lawton CA, Moulder JE. Bone marrow transplant nephropathy: radiation nephritis revisited. Nephron. 1995;70:217-222.
30. Cohen EP. Radiation nephropathy after bone marrow transplantation. Kidney Int. 2000;58:903-918.
31. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5:255-260.
32. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
33. Stracke S, Helmchen U, von Muller L, Bunjes D, Keller F. Polyoma virus-associated interstitial nephritis in a patient with acute myeloic leukemia and peripheral blood stem cell transplantation. Nephrol Dial Transplant. 2003;18: 2431-2433.
34. Miralbell R, Bieri S, Mermillod B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14:579-585.
35. Lawton CA, Barber-Derus SW, Murray KJ, Cohen EP, Ash RC, Moulder JE. Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients. Int J Radiat Oncol Biol Phys. 1992;23:681-686.
36. Bouchet L, Bolch WE, Blanco HP, et al. MIRD pamphlet no. 19: absorbed fractions and radionuclide S values for six age-dependent multiregional models of the kidney. J Nucl Med. 2003;44:1113-1147.
37. Lambert B, Cybulla M, Weiner SM, et al. Renal toxicity after radionuclide therapy. Radiat Res. 2004;161:607-611.
38. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
39. Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32:549-556.
40. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control. 2002;9:106-113.